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Introduction
A number of birth defect–malformation syndromes,
first characterized by their clinical features, have
since proven to be metabolic disorders caused by
abnormalities in enzymes essential for cholesterol
biosynthesis (1–6). The most common of these, with
an estimated frequency of 1 in 10,000 to 40,000 Cau-
casian births (7–9), is Smith-Lemli-Opitz/RSH syn-
drome (SLOS; MIM 270400) (10) characterized by a
dysmorphic facial appearance; palatal clefting; two-
three toe syndactyly; postaxial polydactyly; malfor-
mations of heart, kidney, genitalia, and lungs; occa-
sional holoprosencephaly; severe to profound men-
tal retardation; and failure to thrive (10, 11). SLOS is
caused by mutations in DHCR7, the gene that codes
for 3β-hydroxysteroid ∆7-reductase (E.C.1.3.1.21), the
enzyme that catalyzes the reduction of the ∆7 double
bond of 7-dehydrocholesterol (7DHC) (cholesta-5,7-
dien-3β-ol) to form cholesterol (cholest-5-en-3β-ol)
(12–15). As a result, cholesterol biosynthesis is hin-
dered, leading to reduced plasma and tissue choles-
terol concentrations and the accumulation of 7DHC
and its epimer 8DHC (cholesta-5,8-dien-3β-ol) in all
tissues (12, 16–18).
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Smith-Lemli-Opitz/RSH syndrome (SLOS), a relatively common birth-defect mental-retardation syn-
drome, is caused by mutations in DHCR7, whose product catalyzes an obligate step in cholesterol
biosynthesis, the conversion of 7-dehydrocholesterol to cholesterol. A null mutation in the murine
Dhcr7 causes an identical biochemical defect to that seen in SLOS, including markedly reduced tis-
sue cholesterol and total sterol levels, and 30- to 40-fold elevated concentrations of 7-dehydrocho-
lesterol. Prenatal lethality was not noted, but newborn homozygotes breathed with difficulty, did not
suckle, and died soon after birth with immature lungs, enlarged bladders, and, frequently, cleft
palates. Despite reduced sterol concentrations in Dhcr7–/– mice, mRNA levels for 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase, the rate-controlling enzyme for sterol biosynthesis, the
LDL receptor, and SREBP-2 appeared neither elevated nor repressed. In contrast to mRNA, protein
levels and activities of HMG-CoA reductase were markedly reduced. Consistent with this finding, 
7-dehydrocholesterol accelerates proteolysis of HMG-CoA reductase while sparing other key proteins.
These results demonstrate that in mice without Dhcr7 activity, accumulated 7-dehydrocholesterol
suppresses sterol biosynthesis posttranslationally. This effect might exacerbate abnormal develop-
ment in SLOS by increasing the fetal cholesterol deficiency.
J. Clin. Invest. 108:905–915 (2001). DOI:10.1172/JCI200112103.
Cholesterol plays an essential role in development
because it is needed to activate the morphogenic sonic
hedgehog (SHH) signal pathway during early gestation
(19), and adverse effects of cholesterol deprivation in
the prenatal period are amply illustrated in SLOS by
the strong inverse dependence of symptom severity and
perinatal mortality on plasma cholesterol levels (8, 20).
In contrast to cholesterol, 7DHC fails to stimulate the
SHH pathway (21). 7DHC also appears to be an espe-
cially potent inhibitor of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase (22), the rate-limit-
ing enzyme for cholesterol biosynthesis, explaining
why plasma total sterol and mevalonic acid concentra-
tions (16, 23, 24) and rates of sterol biosynthesis, as
measured by sterol balance (25), are reduced by an aver-
age of 40–50% in SLOS.
To explore the mechanisms by which 7DHC inhibits
sterol biosynthesis, the mouse Dhcr7 gene was mutated
by homologous recombination to create an animal
lacking measurable Dhcr7 activity. Except for low
8DHC/7DHC ratios, the biochemical phenotype in the
mice was indistinguishable from that in SLOS, and sev-
eral physical and metabolic abnormalities found in
newborn Dhcr7–/– mice have their counterparts in
affected children. As in SLOS, sterol biosynthesis was
highly abnormal in homozygous mice. HMG-CoA
reductase, LDL receptor, and sterol response ele-
ment–binding protein-2 (SREBP-2) mRNA levels were
found to be similar to levels measured in heterozygous
and wild-type littermates, yet tissue total sterol con-
centrations and HMG-CoA reductase protein levels
and activities were markedly reduced. Ancillary in vitro
studies provided the explanation for this seemingly
paradoxical result, demonstrating that 7DHC acceler-
ates proteolysis of HMG-CoA reductase enzyme sever-
al fold. Thus, in the Dhcr7-null mouse, as in children
with SLOS, elevated concentrations of 7DHC suppress
cholesterol synthesis, exacerbating the sterol deficien-
cy and further contributing to abnormal development.
Methods
Generation of Dhcr7–/– mice (Dhcr7Ex8). A genomic cosmid
clone from mouse strain 129Ola (clone
MPMGc121P1353Q3) containing the entire Dhcr7 gene
was obtained from the Resource Centre/Primary Data-
base (Berlin, Germany) (15). The targeting construct in
pBluescript KSII (Figure 1a) contained two fragments
of genomic Dhcr7 DNA, a 1.6-kb neomycin resistance
gene under control of the phosphoglycerokinase (PGK)
promoter from pKO SelectNeo (Lexicon Genetics, The
Woodlands, Texas, USA) in opposite orientation to the
transcription of Dhcr7 and a 2-kb thymidine kinase gene
from pKO SelectTK (Lexicon Genetics). The 5′-region
of homology was a 6.6-kb Dhcr7 ClaI-SfuI fragment
comprising mouse exons 4–7 (corresponding to human
exons 5–8). The 3′-region of homology was a 1.4-kb
EcoRI-SpeI fragment that included the entire 3′-
untranslated region of exon 8 (corresponding to human
exon 9) and an additional nontranscribed genomic
sequence (Figure 1a). Electroporation of embryonic
stem (ES) cells (E14TG2a) was carried out as described
(26). Four correctly targeted ES cell clones were identi-
fied by PCR and homologous recombination was con-
firmed by Southern blot analysis. C57Bl/6 blastocysts
were injected with the correctly targeted ES cells and
implanted into pseudopregnant C57Bl/6 females.
Chimeric mice were identified by their coat color (agouti)
and bred. Several pups carrying the modified Dhcr7 gene
were identified, indicating that the mutation had
passed into their germ cells. For genotype analysis, 450
bp of exon 8 of the wild-type gene was amplified using
primer a, 5′ggatcttctgagggcagcctt, and primer b, 5′tct-
gaacccttggctgatca, while the 320-bp fragment of the
mutant allele was amplified by primers neo, 5′ctagac-
cgcggctagagaat, and primer b (Figure 1a).
Immunoblot analysis of Dhcr7 expression was car-
ried out by separating proteins on 14% SDS-polyacry-
lamide gels, then analyzing them by immunoblotting
with 1 mg/ml α-DHCR7454-467 as described previous-
ly (15). Loading of the gels with total liver protein over
a range 80:1 results in corresponding reductions in
Dhcr7 antibody response (Figure 1d, upper panel). In
the lower panel of Figure 1d, microsomal protein
from yeast strains (WA0) and human tsA-201 cells
(tsA) heterologously expressing DHCR7 with an N-
terminal myc tag (15) and from livers of newborn
mice of the indicated genotype were separated. Equal
loading was verified by coincubation with antibodies
against the σ1-receptor (control) as described (15). No
DHCR7 was detected in mock-transfected yeast
(MOCK), while the level of immunoreactive protein
was markedly increased in transfected compared with
mock-transfected tsA cells.
Affinity-purified polyclonal Ab’s (α-DHCR7454-467),
raised in rabbits against amino acid residues 454-467
(YGRDWERYTAAVPY) of human DHCR7, were pur-
chased from BioChem Pharm (Salzburg, Austria).
Biochemical measurements. Sterols were purchased from
Steraloids Inc. (Newport, Rhode Island, USA), except 7-
dehydrodesmosterol (cholesta-7,24-dien-3β-ol), which
was obtained from the plasma of a rat 72 hours after
the simultaneous administration of the ∆7-reductase
inhibitor BM 15.766 and the ∆24-reductase inhibitor
triparanol. Tissue sterols were measured as their
trimethylsilyl ether derivatives using capillary column
gas chromatography (GC) (12, 27), while microsomal
sterols, sterols from cultured cells, and 7DHC in
Dhcr7+/– and wild-type pups were quantitated using
GC/selected ion-monitoring mass spectrometry by
measuring the intensities of the 329, 325, and 343 m/z
peaks for cholesterol, 7DHC, and desmosterol, respec-
tively (22, 28). Because 7DHC and desmosterol have
similar GC retention times 7DHC levels in tissues from
Dhcr7+/– and wild-type animals, especially brain, were
corrected for the presence of desmosterol by using
325:343 m/z ratios. Glucose was measured with a Fast
Take glucometer in blood obtained by decapitation less
than 12 hours after birth.
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Enzyme activities. Dhcr7 activity was assayed by a mod-
ification of the method described by Shefer et al. (13)
because we found it necessary to use whole tissue
homogenate rather than microsomes to achieve repro-
ducible results. Briefly, 0.5 mg protein was incubated
in 150 µl of 100 mM phosphate buffer (pH 7.4) con-
taining a NADPH-generating system plus 30 nmol of
[3H]-7DHC (25,000 dpm). HMG-CoA reductase activi-
ties were measured in isolated liver and brain micro-
somes as described previously (29).
Measurement of mRNA. Total RNA was extracted from
freshly harvested liver with Trizol (Life Technologies,
Bethesda Maryland, USA), according to the manufac-
turer’s recommendation and Northern analysis per-
formed as described previously (30). Mouse cDNA
probes for HMG-CoA reductase, HMG-CoA synthase,
LDL receptor (LDLR), and squalene synthase have been
described previously (30) and were gifts from Hitoshi
Shimano and Jay Horton (University of Texas South-
western Medical Center, Dallas, Texas, USA). Dhcr7
mRNA was measured by RT-PCR after first isolating
total RNA from 5 mg of mouse liver and brain, then
carrying out oligo dT-primed reverse transcription of 2
µg of RNA followed by PCR using the sense/antisense-
specific primer pair for the 3′ transcript of Dhcr7 (915:
5′gaccatcgacatctgccatgacc/ 1870: 5′ggagcctagct-
caccaggatgg; fragment size: 955 bp). GAPDH mRNA
was obtained from the same aliquots of reverse-tran-
scribed cDNA using PCR with the specific sense/anti-
sense primer pairs 5′cagtatgactccactcacg/5′atcgaaggtg-
gaagagtgg (fragment size 747 bp). Signal intensities
were quantified by phosphorimaging analysis after
background subtraction, and all were normalized to
the signal obtained with GAPDH.
HMG-CoA reductase and LDLR protein immunoblotting.
Fifty micrograms of liver homogenate was subjected to
SDS gel electrophoresis on 7.5% slab gels (31). The sepa-
rated proteins were transferred to PVDF Plus mem-
branes, blocked with 5% nonfat dry milk in PBS-Tween,
incubated for 2 hours with a 1:5,000 dilution of HMG-
CoA reductase(32) or LDLR antisera (33), then incubat-
ed for 1 hour with a 1:100,000-diluted goat anti-rabbit
IgG conjugated with horseradish peroxidase (The Jack-
son Laboratory, Bar Harbor, Maine, USA). Reductase
immunoreactive protein was detected with an ECL kit
(Amersham Pharmacia Biotech Inc., Piscataway, New Jer-
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Figure 1
(a) Disruption of the Dhcr7 gene. The coding sequence of exon 8 and the 5′ flanking splice acceptor site and part of the 3′ flanking untrans-
lated region (indicated in gray) of the wild-type gene were replaced with a neomycin resistance gene in opposite orientation to Dhcr7 tran-
scription. Restriction sites used for subcloning of short and long Dhcr7 gene segments are shown. The targeting construct was linearized with
ClaI (arrow). Primers employed for PCR genotyping are labeled a, b, and neo (see Methods). (b) Tentative topology model of Dhcr7. The
induced Dhcr7 mutation is expected to delete one-third of the Dhcr7 protein (the residues shown as filled circles). The box indicates the
putative sterol-binding site REF. (c) Total RNA extracted from the livers of Dhcr7–/–, Dhcr7+/–, and wild-type newborn mice was reverse tran-
scribed and amplified using specific primers for the 3′-end of Dhcr7 mRNA and GADPH. (d) Immunoblot analysis of Dhcr7. Upper panel:
Loading decreasing amounts of total hepatic protein results in corresponding reductions in Dhcr7 Ab response. Lower panel: Microsomal
protein from yeast (WA0) and human tsA-201 cells (tsA) heterologously expressing DHCR7 with an N-terminal myc tag (15) and from liv-
ers of newborn wild-type mice demonstrated immunoreactive Dhcr7 protein. Bands corresponding to myc-tagged (myc) and wild-type (WT)
DHCR7/Dhcr7 proteins, respectively, are indicated by arrowheads. In contrast, no immunoreactive band corresponding to wild-type Dhcr7
was detected in 40 µg of microsomal protein from either homozygous mice (last two lanes) or mock-transfected yeast (MOCK).
sey, USA). Membranes were stripped then reprobed with
a 1:5,000 dilution of β-actin Ab (Sigma Chemical Co., St.
Louis, Missouri, USA). The amount of immunoreactive
HMG-CoA reductase protein present was determined
with an Image Quant 5.1 System.
In vitro measurements of HMG-CoA reductase enzyme
catabolism. Stability of HMG-CoA reductase was stud-
ied in an in vitro system developed by Simoni and col-
leagues, which employs a fusion gene (HMGal) consist-
ing of exons coding for the transmembrane domain of
HMG-CoA reductase coupled to the β-galactosidase
promoter and gene stably transfected into Chinese
hamster ovary (CHO) cells. In this system the β-galac-
tosidase activity acts as a reporter for HMG-CoA reduc-
tase protein levels and activities (34). A pTRE HMGal
plasmid was generated by insertion of full-length
HMGal cDNA sequences (EcoRI/Xbal fragment) into a
pTRE-Off vector (CLONTECH Laboratories Inc., Palo
Alto, California, USA), then cotransfected with pTK
Hyg DNA (CLONTECH Laboratories Inc.) into stable
Tet-Off CHO-AA8 cells (CLONTECH Laboratories
Inc.) in a ratio of 20:1 by lipofection using a Lipofecta-
mine PLUS kit (Life Technologies Inc.), according to
the manufacturer’s instructions. Transfectants were
selected with 0.6 mg/ml hygromycin B for 14 days, and
resistant colonies with the highest β-galactosidase
activity were isolated using fluorescence-activated cell
sorting (35). Cells were maintained in 5% FBS minimal
essential medium (FBS-MEM) supplemented with
nonessential amino acids, 0.1 mg/ml active G418, and
0.2 mg/ml hygromycin B in a humidified 5% CO2 incu-
bator at 37°C, and passaged every 3 days until use.
To measure β-galactosidase activity (34) cells were
seeded as triplicates in 24-well dishes with 5%
FBS-MEM. After incubating for 20 hours, they were
then treated with 5% lipid-poor fetal calf serum–MEM
(LPS-MEM) (36) supplemented with 10 µM com-
pactin (a generous gift from Akira Endo, Tokyo Noko
University, Tokyo, Japan), 0.1 mM sodium meval-
onate, and various concentrations of 7DHC or cho-
lesterol. After an additional 20-hour incubation, cells
were permeabilized with 50 µg/ml digitonin and incu-
bated at 37°C with a 1 mg/ml concentration of the
colorimetric enzyme substrate o-nitrophenyl
β-o-galactopyranoside until a color change was visu-
ally detectable. Reactions were stopped by addition of
1 M Na2CO3, and specific activity values were calcu-
lated by normalization to time of incubation and
total protein (37). Specific activity values are the mean
of three independent experiments.
HMG-CoA reductase and HMGal protein degradation
rates were determined in pulse-chase experiments as
described previously (38). Cells were grown in 60-mm
dishes to 70–80% confluence in 5% FBS-MEM. The fol-
lowing day, the medium was changed to 5% LPS-MEM
medium containing 10 µM compactin and 0.1 mM sodi-
um mevalonate with or without the addition of 7DHC or
cholesterol. After a 20-hour incubation, cells were starved
for 1 hour in methionine/cysteine-free MEM supple-
mented with 10 µM compactin, 0.1 mM sodium meval-
onate, and 7DHC or cholesterol, then labeled for 0.5 hour
in methionine/cysteine-free MEM containing 10 µM
compactin, 0.1 mM sodium mevalonate, 100 µCi of Tran
35S-label, and 7DHC or cholesterol. Cells were chased in
5% LPS-MEM containing 10 µM compactin, 0.1 mM
sodium mevalonate, 2 mM methionine, 2 mM cysteine,
and 7DHC or cholesterol to various time points. At each
time point, cells were washed and solubilized, HMG-CoA
reductase and HMGal proteins immunoprecipitated
with anti-membrane domain HMGR Ab’s and
anti–β-galactosidase mAb’s. The immunoprecipitated
[35S]-labeled HMG-CoA reductase and HMGal proteins
were resolved by 5 to 15% gradient SDS-PAGE and quan-
tified by fluorography and densitometry.
In addition, because we had reported that ketocona-
zole, an inhibitor of sterol side-chain hydroxylation,
appeared to blunt the suppressive effects of 7DHC on
HMG-CoA reductase activity in cultured fibroblasts
(22), HMGal catabolism was also measured in the pres-
ence of 10 µg/ml 7DHC plus 30 µM ketoconazole.
To quantify HMG-CoA reductase catabolic rates, the
data were transformed to protein half-live values as fol-
lows. The quantity of 35S in immunoprecipitated HMG-
CoA reductase or HMGal following a chase with unla-
beled methionine was assumed to decline according to
first-order kinetics so that 35S activity = S0 exp(–αt). Half-
lives were calculated by converting the percentage of
radioactivity remaining at each time point t to its natu-
ral log, plotting ln (35S activity) against time, estimating
the resulting slope α by a least-squares fit, then com-
paring slopes by one-way analysis of covariance (RS/1;
Brooks Automation Inc., Chelmsford, Massachusetts,
USA), stratifying according to the concentration of
added 7DHC. The half-life was set equal to (ln 2)/α,
and, to allow for nonlinearity at the earliest time points,
the ordinate was not fixed at 100% but the least-squares
process was allowed to find a best fit for S0.
Statistics. Concentrations and activities are expressed
as mean plus or minus SD with differences assessed by
the student’s t test or ANOVA, where appropriate, and
significance accepted when P values were less than 0.05.
Animals. Except where noted, all pups were killed
within the first day and either examined under a dis-
secting microscope, or their tissues were removed
immediately, placed on dry ice, and reserved for further
analysis. Care was taken to harvest tissues only from
living animals and to transfer them immediately to dry
ice. It was, however, impossible to compare the relative
physical conditions of the newborn Dhcr7–/– pups
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Figure 2
Genotyping of Dhcr7–/–, Dhcr7+/–, and Dhcr7+/+ newborn mice from
heterozygous matings by PCR using primers specific for mouse exons
7 and 8 as described in Methods and in Figure 1a.
because they all appeared to be inert but still breathing.
Matings were of F1, F2, and F3 heterozygotes and con-
trols were newborn Dhcr7+/– and Dhcr7+/+ pups. Experi-
ments were carried out under protocols approved by
the institutional animal care and use committees of the
University of North Carolina at Chapel Hill, Medical
University of South Carolina, the Bundesministerium
für Wissenschaft und Forschung (Innsbruck, Austria),
Veterans Affairs Medical Center (East Orange, New Jer-
sey, USA), and UMDNJ–New Jersey Medical School.
Results
Targeted mutation of the Dhcr7 locus eliminates enzyme activi-
ty. The most frequently encountered DHCR7 mutation
in SLOS patients (IVS8-1G→C) causes aberrant splicing
of the last exon and leads to a frameshift and truncation
of the gene product (15). The few SLOS patients homozy-
gous for this defect are among the most severely affected
SLOS patients, and the mutation appears to be a null
allele (18). To completely inactivate Dhcr7 we created a
mutation analogous to IVS8-1G→C by deleting the last
exon (exon 8) and its flanking splice acceptor site in the
mouse gene (Figure 1a), thereby removing the sequence
for amino acid residues 318–471 (Figure 1b) that code for
approximately one-third of the protein. This deletion pre-
vents transcription of two putative transmembrane seg-
ments that contain part of a predicted sterol-sensing
domain and an extended hydrophilic sequence thought
to form a large cytosolic loop (39). Analysis of genomic
DNA (Figure 2) verified the engineered genomic alter-
ations shown in Figure 1a. As expected from the nature
of the targeted Dhcr7 mutation, RT-PCR could not ampli-
fy the deleted 3′-coding region of Dhcr7 mRNA in liver
(Figure 1c) or brain (not shown) from pups homozygous
for the Dhcr7delEx8 allele while Dhcr7-specific Ab’s failed to
detect the Dhcr7 protein in Dhcr7–/– mice (Figure 1d). In
contrast, 5′-exonic regions of Dhcr7, which were not delet-
ed by the mutation, were amplified successfully (data not
shown), indicating that the targeted gene was transcribed.
Dhcr7 activities from homozygous newborns were virtu-
ally undetectable (1 ± 1 pmol/mg protein/min), while
enzyme activities in heterozygotes were close to half of
that noted in wild-type mice (Figure 3).
Dhcr7∆Ex8 mice display developmental abnormalities and die
perinatally. Heterozygous matings resulted in litters
that averaged 6–7 animals (range 2–12) yielding 61
homozygotes, 130 heterozygotes, and 60 wild-type ani-
mals in 251 consecutive newborns (approximately half
male and half female) examined within 14 hours of
birth. As this result closely approximates the expected
Mendelian ratio, homozygotes do not die prenatally.
Pups lacking Dhcr7 activity, however, were easily iden-
tified shortly after birth by their labored breathing,
blue coloration, and lack of movement, while het-
erozygous and wild-type littermates appeared to be
identical in physical appearance and size to each other.
None of the Dhcr7–/– pups suckled, and they weighed
significantly less (P < 0.001) than their Dhcr7+/– and
wild-type littermates (1.14 ± 0.10 g, n = 15, vs. 
1.41 ± 0.15 g, n = 38, and 1.42 ± 0.13 g, n = 17, respec-
tively). Blood glucose levels (92 ± 11, 94 ± 17, and 
96 ± 21 mg/dl, respectively; P = NS) were similar in all
animals. All homozygotes died within 18 hours, pre-
sumably from respiratory failure or dehydration. His-
tological analysis showed no gross abnormalities of
brain, heart, intestine, adrenal gland, or kidney. How-
ever, microscopic examination of fixed and stained sec-
tions of lung sections from Dhcr7–/– mice demonstrat-
ed compact lungs with sparse, unconnected air spaces
(Figure 4) that were similar in appearance to normal
15- to 16-gestational day mice (40). These results sug-
gest that lungs in newborn Dhcr7–/– mice may be imma-
ture and would explain their breathing difficulties and
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Figure 3
Activity of Dhcr7 (picomoles per milligram of protein per minute) as
measured by the conversion of [3H]-7DHC to cholesterol in liver
homogenates from newborn Dhcr7–/–, Dhcr7+/–, and Dhcr7+/+ mice.
Figure 4
Palates were unremarkable in newborn Dhcr7+/–and Dhcr7+/+ mice (a)
but were frequently cleft in Dhcr7–/– newborns (b), while bladders were
of normal size in controls (c) but were nearly always distended (indi-
cated by arrows in the opened abdomen) in Dhcr7–/– mice (d). ×10.
early death. Although not seen in any Dhcr7+/– or
Dhcr7+/+ littermates, isolated cleft palates were noted in
12% of Dhcr7–/– pups (Figures 5, a and b), while more
than 90% of Dhcr7–/– newborns but no Dhcr7+/– or
Dhcr7+/+ mice exhibited greatly distended urinary blad-
ders (Figures 5, c and d).
Sterol abnormalities in Dhcr7–/– mice and humans with
SLOS are similar. Cholesterol and total sterol (choles-
terol plus dehydrocholesterol) concentrations were sig-
nificantly reduced, while levels of 7DHC and 8DHC
were increased 30- to 40-fold in isolated liver micro-
somes, in whole liver, and in brain homogenates from
Dhcr7–/– newborn mice (Table 1). Except for
8DHC/7DHC ratios that were lower than those noted
in humans (16, 20), sterol compositions in Dhcr7–/–
mice closely resembled that in SLOS. Cholesterol
deficits in homozygous mice were most profound in
the brain with dehydrocholesterols making up 80% of
total sterols. Furthermore, although desmosterol
(cholesta-5,24-dien-3β-ol) constituted nearly 20% of
neutral sterols in the Dhcr7+/– and Dhcr7+/+ newborn
mouse brain, this cholesterol precursor was not detect-
ed in Dhcr7–/– mice, which instead accumulated 7-dehy-
drodesmosterol (cholesta-5,7,24-trien-3β-ol).
Plasma cholesterol levels, 111 ± 27 mg/dl and 82 ± 16
in heterozygous breeders and wild-type adult mice,
respectively (n = 6, P = NS), were similar. Liver cholesterol
concentrations in 23-day-old Dhcr7+/– and Dhcr7+/+ pups
were identical (2.7 ± 0.4 mg/g vs. 2.8 ± 0.6 mg/g, respec-
tively; n = 4) and were similar in composition to newborn
Dhcr7+/– and Dhcr7+/+ livers. Unlike liver, however, cho-
lesterol levels in Dhcr7+/– and Dhcr7+/+ mouse brains
increased threefold to fourfold in the first 3 weeks of life,
while desmosterol concentrations fell nearly tenfold
(Table 2). Except for subtly elevated 7DHC levels, het-
erozygous animals appeared otherwise normal, so there
was only a minor biochemical phenotype associated with
the effect of haploinsufficiency on Dhcr7 activity.
HMG-CoA reductase activities and enzyme protein, but not
mRNA levels, were markedly reduced in Dhcr7–/– newborns.
Consistent with low total sterol concentrations in
Dhcr7–/– mice, HMG-CoA reductase activities were
reduced sixfold in liver and 2.7-fold in brain micro-
somes (Table 3), while levels of HMG-CoA reductase
protein were reduced commensurately (Figure 6a)
compared with Dhcr7+/– and Dhcr7+/+ littermates. Gen-
eralized protein degradation, however, was not a fea-
ture of the homozygous mice because levels of LDLR
(Figure 6b) and β-actin concentrations appeared to be
similar in all animals. In contrast to HMG-CoA reduc-
tase activity, mRNA levels for HMG-CoA reductase as
well as for HMG-CoA synthase, squalene synthase,
LDLR, SREBP-1, and SREBP-2 were similar in Dhcr7–/–,
Dhcr7+/–, and Dhcr7+/+ newborns (Figure 7).
7DHC accelerates catabolism of HMG-CoA-reductase protein.
7DHC, but not cholesterol, reduced levels of steady state
β-galactosidase activity in a dose-dependent manner in
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Figure 5
Histological sections of control mouse lung, (a) ×10 and (b) ×40,
and Dhcr7–/– mouse lung, (c) ×10 and (d) ×40, illustrating lung
hypoplasia in the latter. Especially noteworthy is the excessive cellu-
lar density, the failure of the lungs to fill the pleural cavity (*), and
their immature appearance.
Table 1
Sterol concentrations in whole brain, whole liver, and liver microsomes from newborn Dhcr7–/– compared with pooled Dhcr7+/– and 
wild-type mice
Sterol Whole brain Whole liver Liver microsomes
–/– +/– and +/+ –/– +/– and +/+ –/– +/– and +/+
(n = 4) (n = 14) (n = 11) (n = 14) (n = 3) (n = 4)
mg/g wet weight (mean ± SD) µg/mg protein (mean ± SD)
Cholesterol 0.46 ± 0.10A 3.41 ± 0.48 0.58 ± 0.47A 3.19 ± 0.77 17 ± 4B 55 ± 11
7DHC + 8DHCC 1.64 ± 0.92A 0.03 ± 0.02D 0.39 ± 0.23A 0.01 ± 0.02E 10 ± 4B 1 ± 1
Desmosterol — 0.81 ± 0.12 — — — —
7-Dehydro- 0.42 ± 0.14A — — — — —
desmosterol
Total sterols 2.52 ± 1.13A 4.25 ± 0.59 1.02 ± 0.66A 3.20 ± 0.86 27 ± 8A 56 ± 11
% 7DHC + 8DHC 80 ± 4 0.6 ± 0.4F 47 ± 12A 0.5 ± 0.70 44 ± 20B 0.01 ± 0.01
Cholesterol levels in brain and liver from Dhcr7+/– and wild-type mice were similar. AP < 0.002 vs. pooled Dhcr7+/– and Dhcr7+/+. BP < 0.02 vs. pooled Dhcr7+/– and
Dhcr7+/+. C8DHC/7DHC ratios were 0.12 ± 0.11 in liver and 0.09 ± 0.02 in brain. D7DHC + 8DHC = 0.035 ± 0.014 mg/g (Dhcr7+/–, n = 9) vs. 0.0092 ± 0.0041
mg/g in (Dhcr7+/+, n = 5), P < 0.005. E7DHC + 8DHC = 0.020 ± 0.024 (Dhcr7+/–, n = 9) vs. 0.010 ± 0.019 (Dhcr7+/+, n = 5), P = NS. F7DHC + 8DHC = 0.82 ± 0.27%
(Dhcr7+/+, n = 9) vs. 0.22 ± 0.11% (Dhcr7+/+, n = 5), P < 0.001.
CHO cells transfected with the HMGal construct (Figure
8). Incubating these cells for 24 hours with 10–20 µg/ml
7DHC raised their 7DHC/cholesterol ratio to levels sim-
ilar to those measured in the livers of Dhcr7–/–mice while
reducing activity to 40–50% of pretreatment values. After
a 24-hour incubation following the addition of 1 µg/ml
and 10 µg/ml 7DHC to the culture medium (Figure 9),
HMG-CoA reductase half-lives were reduced to 3.8 ± 0.2
and 2.5 ± 0.4 hours, respectively, compared with 9.2 ± 2.3
hours in cells grown without exogenous precursor sterol
(P < 0.05). Similarly, HMGal half-life, 5.0 ± 0.7 hours in
control cells, was shortened to 2.7 ± 0.2 hours and 
2.0 ± 0.4 hours (P < 0.005) in cells incubated with 1 and
10 µg/ml 7DHC, respectively (Figure 10).
Suppressing hydroxylation of the sterol side chain
had no effect on the stability of HMGal. Half-lives
measured in cells incubated for 24 hours in the pres-
ence and absence of 30 µM ketoconazole were 4.1 ± 0.4
and 5.0 ± 0.7, respectively (P = NS), while half-lives in
cells grown under identical conditions but after adding
10 µg/ml 7DHC were 2.6 ± 0.1 and 2.0 ± 0.4 hours,
respectively (P = NS).
Discussion
In tissues from Dhcr7–/– mice, despite the application of
a very sensitive and specific technique for the amplifi-
cation and detection of the transcript for the 3′-end of
Dhcr7, none could be found, no Dhcr7 immunoreactive
protein was observed, and Dhcr7 enzyme activity could
not be detected. Furthermore, Dhcr7 mRNA levels and
Dhcr7 activities in Dhcr7+/– mice were reduced by
approximately 50% compared with their Dhcr7+/+ litter-
mates (Figures 1 and 3). Thus, gene targeting was suc-
cessful, and Dhcr7∆Ex8 is a null allele unable to reduce
7DHC to cholesterol. The targeted mouse recapitulat-
ed most of the biochemical defects described in SLOS
with 7DHC levels elevated 30- to 40-fold, and choles-
terol and total sterol concentrations were markedly
reduced. In addition, because the biosynthesis of
desmosterol requires the reduction of a ∆7 double
bond, 7-dehydrodesmosterol, a compound that retains
double bonds at both C-7,8 and C-24,25 accumulated
in the brains of Dhcr7–/– pups (Table 1). Unlike SLOS,
however, in which 8DHC and 7DHC concentrations
are nearly equal (16, 20), 8DHC/7DHC ratios in new-
born Dhcr7–/– mice were closer to 0.1 (Table 1).
The cholesterol/7DHC ratios in livers of newborn
homozygous mice were considerably higher than
ratios noted in the most severely affected children
with SLOS, that is in those individuals predicted to
be without DHCR7 activity (8, 18, 20). This result
suggests that the fetal mouse receives a greater pro-
portion of its cholesterol from its mother than does
the human fetus, in agreement with numerous obser-
vations that maternal cholesterol is obligate for
murine (41–43) but not for human (44) development
and that considerable amounts of maternal choles-
terol are probably transferred to the fetus early in
rodent gestation (45, 46). The gross structural fea-
tures of most organs are set within the first 7–10 ges-
tational days in rats and mice. Thus, using athero-
genic diets to raise plasma cholesterol levels in
pregnant rats being treated with DHCR7 inhibitors
probably enabled the mothers to transfer enough
extra cholesterol to the fetuses to abolish most
abnormal development (47). Because mice normally
have much higher plasma cholesterol levels than rats,
one has difficulty in generating fetal mice with severe
abnormalities using these same inhibitors (48). Ele-
vated cholesterol transfer from mother to fetus early
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Figure 6
Immunoblot analysis of 50 µg of liver protein for (a) HMG-CoA
reductase (HMGR) and (b) LDLR in Dhcr7+/+, Dhcr7+/–, and Dhcr7–/–
newborn mice demonstrating significantly reduced levels of HMG-
CoA but not LDLR protein in homozygous animals. Relative intensi-
ties of each band normalized to β-actin are listed below the blots.
Levels of β-actin present in each lane were nearly identical, indicat-
ing equal loading and transfer (not shown).
Figure 7
Northern blot analysis of (a) hepatic HMG-CoA reductase, HMG-
CoA synthase, squalene synthase, LDLR, SREBP-1, and SREBP-2, and
(b) RT-PCR–amplified brain HMG-CoA reductase and LDLR mRNA
extracted from Dhcr7–/–, Dhcr7+/–, and Dhcr7+/+ newborn mice,
demonstrating that expression of all of the genes is the same in the
three genotypes. Intensities in both a and b were normalized to
GAPDH mRNA. These are representative samples of blots carried out
in three Dhcr7–/– mice.
in gestation is also likely to be the reason that the
Dhcr7–/– mice did not develop more of the SLOS-like
craniofacial and limb abnormalities.
Although embryonic lethality was not noted in
homozygous mice, some developmental abnormalities
including incomplete lung development, distended
bladders, and cleft palates were seen and all Dhcr7–/–
mice died within 18 hours of birth from “failure to
thrive” with respiratory failure. While palatal clefting
and lung abnormalities are found in nearly half of all
SLOS patients, the latter usually consist of lobular
defects while cellular immaturity has not as yet been
reported (49). The exact molecular pathways by which
alterations in sterol composition perturb development
are not entirely certain but two possibilities seem rele-
vant to this study. Development of lung and bladder,
and a number of other organ systems, depends on the
sonic hedgehog/patched/smoothened/Gli protein
family pathway (50, 51) and inappropriate signaling
resulting from Shh gene modification leads to abnor-
mal epithelial/mesenchymal interactions (50) and
defective lung development in mice (52). Because prop-
er functioning of Shh requires cholesterol (53) and
7DHC does not permit Shh to be activated (21, 54), it
was not surprising to find abnormal development in
organs that use this signal pathway. Unlike lung and
bladder, palatal clefting, noted in 50% of children with
SLOS (8) and 12% of Dhcr7–/– mice, may be somewhat
dependent on abnormal folate metabolism (55). The
folate receptor is a glycosylphosphatidylinositol-bound
protein complex probably sorted to caveolae or other
regions of the cell membrane having a high sterol con-
tent and that might be specially sensitive to lipid com-
position (56). For instance, SLOS fibroblasts grown in
a cholesterol-free medium so as to increase their 7DHC
concentration develop membrane-specific defects
including increased fluidity and reduced hydrolysis of
membrane phosphoinositol (57), all of which might
contribute to palatal clefting.
Sterol biosynthesis is suppressed in the average child
with SLOS (16, 22, 23, 25). Biosynthesis is also reduced
by similar amounts in Dhrc7–/– mice as percentage of
reductions in liver total sterols, HMG-CoA reductase
protein levels, and HMG-CoA reductase activities (68%,
64%, and 83%, respectively) are comparable. Similar dif-
ferences were also noted in the mouse brain, with the
exception that the magnitude of HMG-CoA reductase
activities in the brains of all mice were several-fold
higher than those noted in the liver. This greater activ-
ity reflects the increased need for cholesterol by the
CNS soon after birth, illustrated by the fourfold rise in
brain, but not liver, cholesterol in 23-day-old compared
with newborn mice (Tables 1 and 2). Markedly elevated
HMG-CoA reductase activity also explain why, com-
pared with other organs, cholesterol and total sterol
deficits are much larger in the brains of both Dhcr7–/–
mice and severely affected human fetuses (16).
In contrast to activities and protein concentrations,
mRNA levels for HMG-CoA reductase, and for number
of other genes critical for cholesterol synthesis and
metabolism, appeared to be similar in all of the new-
born mice (Figure 7). Cholesterol homeostasis is nor-
mally maintained by a tightly controlled coordinate reg-
ulation of a number of genes modulated, for the most
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Figure 8
β-galactosidase activity in CHO cells transfected with the HMGal con-
struct and driven by the galactosidase promoter. Cells were incubat-
ed for 24 hours with increasing concentrations of either 7DHC or
cholesterol before determining activity. Because HMG CoA reduc-
tase activity is known to be proportional to HMGal activity in this
system, these results demonstrate that 7DHC, but not cholesterol,
causes excessive destruction of HMG CoA reductase enzyme protein.
Figure 9
The percentage of [35S]-HMG-CoA reductase remaining 1.5, 3.5,
and 5.5 hours after a chase with unlabeled methionine in CHO cells
incubated for 24 hours in the presence or absence of 1 and 10
µg/ml 7DHC, demonstrating a dose-dependent acceleration of
enzyme catabolism by 7DHC.
part, by the microsomal protein SREBP-2. When intra-
cellular cholesterol levels are sensed as being too low,
SREBP-2 is cleaved from the endoplasmic reticulum
(ER), releasing a nuclear transcription factor that upreg-
ulates expression of HMG-CoA reductase, HMG-CoA
synthase, squalene synthase, LDLR, and SREBP-2 (58).
Thus, for example, treating rats with the squalene syn-
thase inhibitor zaragozic acid and reducing hepatic cho-
lesterol levels by 40% induces a fourfold to fivefold
increase in HMG-CoA reductase and LDLR transcrip-
tion rates, mRNA levels, and protein concentrations,
and in HMG-CoA reductase activities (59, 60). Yet, in
Dhcr7–/– mice, despite similar reductions in total sterol
concentrations and much greater reductions in tissue
cholesterol levels, the SREBP-2–modulated pathway
seems not to be activated (Figure 7). It may be that
7DHC perturbs (57, 61) the ER membrane, making
cleavage of the active nuclear transcription factor more
difficult, or changes membrane properties so as to pre-
vent the cycling of SCAP to the Golgi apparatus so that
it can be modified and activated (62). However, because
LDLR mRNA and protein levels were similar in both
affected, wild-type, and heterozygous mice, high levels
of 7DHC seem not to interfere with translation.
Unchanged mRNA levels would not, under any cir-
cumstances, explain why HMG-CoA reductase protein
levels are depressed in homozygous mice or why de
novo sterol synthesis is inhibited. But, the combination
of normal HMG-CoA reductase and LDLR mRNA and
reduced protein levels for HMG-CoA reductase, but not
for LDLR or β-actin, suggested that 7DHC might be
accelerating the degradation of HMG-CoA reductase
itself. We assayed the effect of 7DHC on the catabolism
of HMG-CoA reductase using a well-established in
vitro model that employs CHO cells transfected with
the HMGal construct, which consists of the transmem-
brane region of HMG-CoA reductase fused to the
reporter β-galactosidase gene and its promoter. This
portion of the HMG-CoA reductase protein is suffi-
cient to initiate the HMG-CoA reductase proteolytic
cascade, which, at the same time, also degrades β-galac-
tosidase. Thus, in this system, HMG-CoA reductase
activity and protein levels are both proportional to 
β-galactosidase activity (34, 38). Furthermore, because
expression is driven by the galactosidase, not the HMG-
CoA reductase, promoter assays are carried out under
conditions of constant gene expression unrelated to
either cholesterol or isoprenoid concentrations.
The addition of sufficient 7DHC to raise the
7DHC/cholesterol ratio to a level nearly equal to that
in the livers of Dhcr7–/– mice suppressed steady-state 
β-galactosidase activity by about 50% (Figure 8), a value
similar to the reduction in HMG-CoA reductase activ-
ity and protein noted in these animals. In contrast to
7DHC, cholesterol had no effect on activity. These
results, taken together, suggest that 7DHC probably
destabilizes HMG-CoA reductase enzyme. We were able
to prove that this is indeed the mechanism that causes
reduced sterol biosynthesis in Dhcr7–/– mice and in
patients with SLOS by incubating CHO cells with
7DHC and finding that the half-lives of HMG-CoA
reductase (Figure 9) and HMGal (Figure 10) both
decreased threefold when cellular 7DHC increased to
about 30% of total sterols.
HMG-CoA reductase is an ER protein that is degraded
within its transmembrane region by a membrane-bound
cysteine protease (35, 63). It normally has a half-life of
only a few hours, and its stability is reduced by Ca2+
depletion (38), perhaps involving a specific Ca trans-
porter (64), and by the addition of mevalonate or meval-
onate-derived sterols (65, 66). Nevertheless, in the
Dhcr7–/– mouse and in SLOS, despite reduced tissue total
sterol concentrations and plasma mevalonate levels (24),
HMG-CoA reductase protein appears to be degraded at
a highly accelerated rate. This result, in turn, suggests
that 7DHC has an effect within the ER membrane con-
trary to that of cholesterol or isoprenoid cholesterol pre-
cursors, and in some manner activates the proteolytic
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Figure 10
The percentage of [35S]-HMGal remaining 1.5, 3.5, and 5.5 hours
after a chase with unlabeled methionine in CHO cells incubated for
24 hours in the presence or absence of 1 and 10 µg/ml 7DHC,
demonstrating a dose-dependent acceleration of HMG CoA reduc-
tase enzyme protein catabolism by 7DHC.
Table 2
Brain sterols in 23-day-old Dhcr7+/– and Dhcr7+/+ mice
Sterol +/– (n = 4) +/+ (n = 4)
mg/g wet weight (mean ± SD)
Cholesterol 15.5 ± 0.9 15.8 ± 1.3
Desmosterol 0.14 ± 0.01 0.15 ± 0.01
7DHC 0.024 ± 0.07A 0.012 ± 0.003
AP < 0.02 vs. Dhcr7+/+.
process. Although it has not been well studied, replacing
cholesterol with 7DHC has a number of effects on mem-
branes, including increasing their thickness and fluidity
as well as their permeability to Ca ions (57). In contrast
to 7DHC, ketoconazole, an inhibitor of sterol side-chain
hydroxylation that mitigates the suppression of HMG-
CoA reductase activity by 7DHC in fibroblast cultures
(22), did not affect the HMGal half-life. This latter result
suggests that, while 27-hydroxylated sterols may well be
important inhibitors of HMG-CoA reductase expression
(67), they probably have little effect on enzyme stability
in physiologic concentrations.
Thus, the 7DHC that accumulates in patients with
SLOS accelerates proteolysis of HMG-CoA reductase
enzyme protein, thereby depriving the developing organ-
ism of needed sterols. Although this effect might be pro-
tective, forestalling even more massive accumulations of
a possibly toxic precursor such as 7DHC, it is just as like-
ly to be deleterious. This would be especially disadvan-
tageous for children with mutations that retain some
DHCR7 activity (18) by suppressing the production of
7DHC and further restricting the amount of cholesterol
available prenatally (68). The newborn Dhcr7-null mouse
is, for many purposes, a good model for SLOS. Howev-
er, because it does not demonstrate many of the more
common abnormalities noted in SLOS, it will have to be
further manipulated (48) to create a system to study
abnormal development. Nevertheless, this mouse has
been especially helpful because it has permitted identifi-
cation of one of the major mechanisms that suppresses
sterol synthesis in children with SLOS.
Note added in proof. During preparation of this manu-
script Wassif et al. published a description of a
SLOS/RSH mouse (69). Using a different targeting
strategy, they created an animal without apparent
Dhcr7 activity but with impaired glutamate uptake by
frontal cortex neurons that demonstrated nearly iden-
tical sterol concentrations and phenotype as the
Dhcr7∆Ex8 mice. Both models have been described before
in abstract form (70–72).
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